Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128381 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
A Phase 1 study of Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML), sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT07128381: Recruiting Phase 1 study of Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML), sponsored by M.D. Anderson Cancer Center.
NCT07128381 is a Phase 1 study of Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 66 participants, below the 975-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07128381, a Phase 1 study of Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML), is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Axatilimab (SNDX-6352)
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2033-07-31 |
| Phase | Phase 1 |
What NCT07128381 shows while recruiting
NCT07128381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 975-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Myelofibrosis (MF) appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT07128381 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07128381 about?
NCT07128381 is a clinical study titled "Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)". * To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
What is the current status of trial NCT07128381?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2026-01-02. Estimated completion is 2033-07-31.
What conditions does trial NCT07128381 study?
This clinical trial studies the following conditions: Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML).
What interventions are being tested in trial NCT07128381?
The interventions under investigation include: Ruxolitinib (DRUG), Axatilimab (SNDX-6352) (DRUG).
Who is sponsoring clinical trial NCT07128381?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128381 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis (MF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
ACTIVE NOT RECRUITING · Phase 1
-
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RECRUITING
-
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
RECRUITING · Phase 2
-
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
COMPLETED · Phase 2
-
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI